

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

			,	www.uspto.gov			
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	TA	TORNEY DOCKET NO.	CONFIRMATION NO.		
09/825,561	04/03/2001	Cindy A. Sprecher		00-22 2838			
759	90 05/08/2002						
Jennifer K. Johnson, J.D. ZymoGenetics, Inc. 1201 Eastlake Avenue East				EXAMINER			
				LI, RUIXIANG			
Seattle, WA 98102				ART UNIT	PAPER NUMBER		
				1646			
			DAT	TE MAILED: 05/08/2002	10		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/825,561	SPRECHER			
		Examiner	Art Unit			
		Ruixiang Li	1646			
	The MAILING DATE of this communication app		l			
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)[Responsive to communication(s) filed on 16 A	<u>pril 2002</u> .				
2a)□	· · · · · · · · · · · · · · · · · · ·	s action is non-final.				
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4)⊠ Claim(s) <u>1-24,31-33 and 35-60</u> is/are pending in the application.						
4a) Of the above claim(s) 1-24,38-47 and 53-60 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)🖾	Claim(s) <u>31, 33, 37, 49, and 53-60</u> are subject	to restriction and/or election requ	uirement.			
Application	on Papers					
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
	Applicant may not request that any objection to the					
11)LT	he proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	oved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) 🔲 Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)			

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

 Applicants' election without traverse of Group II, Claims 25-37 in Paper No. 8 is acknowledged.

2. Applicants' amendment in Paper No. 9 has been entered in full. Claims 25-30 and 34 have been canceled. Claims 1-24 and 38-47 have been withdrawn from further consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. New claims 48-60 have been added.

3. Newly submitted claims 53-60 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the newly submitted Claims 53-60 are drawn to a method of using the receptor polypeptides of Group II and are related to Group II as a product and process of use. The invention can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP §806.05 (h)). In the instance case, the polypeptide may be used in a materially different process, such as to immunize mice to produce antibodies.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 53-60 have been

Art Unit: 1646

withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

- 4. Newly submitted claims 48-52 are related to elected invention Group II. Thus, Claims 1-24, 31-33, and 35-60 are pending. Claims 31-33, 35-37, and 48-52 are under consideration and all other claims are withdrawn from consideration.
- 5. Furthermore, this application contains claims directed to the following patentably distinct species of the claimed invention. (a) Claims 31 and 49 contain SEQ ID NO: 10 and SEQ ID NO: 47; (b) Claims 33 and 37 contain SEQ ID NO: 4 and SEQ ID NO: 82.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species in claims 31 and 49, and a single disclosed species in claims 33 and 37 for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37

Art Unit: 1646

CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (703) 306-0282. The examiner can normally be reached on Monday-Friday, 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564. The fax phone number for this Group is (703) 305-3014 or (703) 308-4242.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file.

PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35

Art Unit: 1646

U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Ruixiang Li Examiner May 1, 2002

> ELIZABETH KEMMERER PRIMARY EXAMINER

Elyabet C. Kemme